Eburon

Eburon is a biotechnology company based in Leiden, Netherlands, dedicated to the research and development of therapies for healthy aging and longevity. Founded in 2024 by Onno van de Stolpe, the visionary founder and former CEO of Galapagos, the company focuses on identifying novel biological targets that influence the aging process. Eburon aims to translate cutting-edge longevity science into therapeutic interventions that can delay or reverse age-related decline and treat associated diseases. The company leverages the extensive drug discovery and development expertise of its leadership team to build a robust pipeline of small molecule candidates. Currently in the pre-clinical stage, Eburon is positioned as a significant new player in the rapidly evolving longevity biotech sector. The company is primarily self-funded by its founder, reflecting a strong commitment to its mission of extending human healthspan.